The Impacts of Short-Term NMN Supplementation on Serum Metabolism, Fecal Microbiota, and Telomere Length in Pre-Aging Phase.

Niu KM, Bao T, Gao L, Ru M, Li Y, Jiang L, Ye C, Wang S, Wu X

Frontiers in nutrition29 Nov 2021Cited by 45 (Europe PMC)

PMID34912838PMCIDPMC8667784DOI10.3389/fnut.2021.756243PepBankPUB-34912838

Summary

Aging is a natural process with concomitant changes in the gut microbiota and associate metabolomes. Beta-nicotinamide mononucleotide, an important NAD⁺ intermediate, has drawn increasing attention to retard the aging process. We probed the changes in the fecal microbiota and metabolomes of pre-aging male mice (C57BL/6, age: 16 months) following the oral short-term administration of nicotinamide mononucleotide (NMN). Considering the telomere length as a molecular gauge for aging, we measured this in the peripheral blood mononuclear cells (PBMC) of pre-aging mice and human volunteers (age: 45-60 years old). Notably, the NMN administration did not influence the body weight and feed intake significantly during the 40 days in pre-aging mice. Metabolomics suggested 266 upregulated and 58 downregulated serum metabolites. We identified 34 potential biomarkers linked with the nicotinamide, purine, and proline metabolism pathways. Nicotinamide mononucleotide significantly reduced the fecal bacterial diversity (p < 0.05) with the increased abundance of Helicobacter, Mucispirillum, and Faecalibacterium, and lowered Akkermansia abundance associated with nicotinamide metabolism. We propose that this reshaped microbiota considerably lowered the predicated functions of aging with improved immune and cofactors/vitamin metabolism. Most notably, the telomere length of PBMC was significantly elongated in the NMN-administered mice and humans. Taken together, these findings suggest that oral NMN supplementation in the pre-aging stage might be an effective strategy to retard aging. We recommend further studies to unravel the underlying molecular mechanisms and comprehensive clinical trials to validate the effects of NMN on aging.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study12

11 results from studies that gave the peptide. 1 result from people.

01HumanNon-randomized trialEfficacy outcome
In human volunteers, NMN significantly elongated PBMC telomeres.
In plain wordsIn human volunteers, NMN increased telomere length in peripheral blood mononuclear cells.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
IncreasePBMC telomere length
Study
n: not reported in source
Outcome group
Aging markers · Aging and longevity
Studied dose
Dose not stated
Source sentences
Summary
Most notably, the telomere length of PBMC was significantly elongated in the NMN-administered mice and humans.
1 context sentence(design, population, supporting numbers)
Summary · context
Considering the telomere length as a molecular gauge for aging, we measured this in the peripheral blood mononuclear cells (PBMC) of pre-aging mice and human volunteers (age: 45-60 years old).
Show in the study text Report a problemFND-3491283811
02AnimalAnimal study (in vivo)Efficacy outcome
In pre-aging mice, NMN did not significantly change body weight during treatment.
In plain wordsIn pre-aging mice, NMN did not significantly change body weight.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
No significant changeBody weight
Study
mousen: not reported in source
pre-aging male C57BL/6 mice
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · oral · 40 daysAs given in this study (mouse).
Source sentences
Summary
Notably, the NMN administration did not influence the body weight and feed intake significantly during the 40 days in pre-aging mice.
1 context sentence(design, population, supporting numbers)
Summary · context
We probed the changes in the fecal microbiota and metabolomes of pre-aging male mice (C57BL/6, age: 16 months) following the oral short-term administration of nicotinamide mononucleotide (NMN).
Show in the study text Report a problemFND-3491283801
03AnimalAnimal study (in vivo)Efficacy outcome
In pre-aging mice, NMN did not significantly change feed intake during treatment.
In plain wordsIn pre-aging mice, NMN did not significantly change food intake.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
No significant changeFeed intake
Study
mousen: not reported in source
pre-aging male C57BL/6 mice
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
Dose not stated · oral · 40 daysAs given in this study (mouse).
Source sentences
Summary
Notably, the NMN administration did not influence the body weight and feed intake significantly during the 40 days in pre-aging mice.
1 context sentence(design, population, supporting numbers)
Summary · context
We probed the changes in the fecal microbiota and metabolomes of pre-aging male mice (C57BL/6, age: 16 months) following the oral short-term administration of nicotinamide mononucleotide (NMN).
Show in the study text Report a problemFND-3491283802
04AnimalAnimal study (in vivo)Efficacy outcome
In pre-aging mice, serum metabolomics after NMN showed 266 upregulated and 58 downregulated metabolites.
In plain wordsIn pre-aging mice, NMN treatment accompanied increases in 266 serum metabolites and decreases in 58 metabolites.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
MixedSerum metabolite profile
Study
mousen: not reported in source
pre-aging male C57BL/6 mice
Outcome group
Metabolic pathways and metabolomics · Metabolic and weight
Studied dose
Dose not stated · oralAs given in this study (mouse).
Measurements
Upregulated metabolites
266 metabolites
serum
Downregulated metabolites
58 metabolites
serum
Source sentences
Summary
Metabolomics suggested 266 upregulated and 58 downregulated serum metabolites.
1 context sentence(design, population, supporting numbers)
Summary · context
We probed the changes in the fecal microbiota and metabolomes of pre-aging male mice (C57BL/6, age: 16 months) following the oral short-term administration of nicotinamide mononucleotide (NMN).
Show in the study text Report a problemFND-3491283803
05AnimalAnimal study (in vivo)Other
In pre-aging mice, analysis identified 34 potential biomarkers linked to nicotinamide, purine, and proline metabolism pathways.
In plain wordsIn pre-aging mice, researchers identified 34 potential biomarkers linked to nicotinamide, purine, and proline metabolism.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
Not applicablePotential metabolic biomarkers
Study
mousen: not reported in source
pre-aging male C57BL/6 mice
Outcome group
Metabolic pathways and metabolomics · Metabolic and weight
Studied dose
Dose not stated · oralAs given in this study (mouse).
Source sentences
Summary
We identified 34 potential biomarkers linked with the nicotinamide, purine, and proline metabolism pathways.
1 context sentence(design, population, supporting numbers)
Summary · context
We probed the changes in the fecal microbiota and metabolomes of pre-aging male mice (C57BL/6, age: 16 months) following the oral short-term administration of nicotinamide mononucleotide (NMN).
Show in the study text Report a problemFND-3491283804
06AnimalAnimal study (in vivo)Efficacy outcome
In pre-aging mice, NMN significantly reduced fecal bacterial diversity.
In plain wordsIn pre-aging mice, NMN reduced fecal bacterial diversity.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
DecreaseFecal bacterial diversity
Study
mousen: not reported in source
pre-aging male C57BL/6 mice
Outcome group
Gut microbiota · Gastrointestinal
Studied dose
Dose not stated · oralAs given in this study (mouse).
Source sentences
Summary
Nicotinamide mononucleotide significantly reduced the fecal bacterial diversity (p < 0.05)
1 context sentence(design, population, supporting numbers)
Summary · context
We probed the changes in the fecal microbiota and metabolomes of pre-aging male mice (C57BL/6, age: 16 months) following the oral short-term administration of nicotinamide mononucleotide (NMN).
Show in the study text Report a problemFND-3491283805
07AnimalAnimal study (in vivo)Efficacy outcome
In pre-aging mice, NMN increased fecal Helicobacter abundance.
In plain wordsIn pre-aging mice, NMN increased Helicobacter abundance in feces.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
IncreaseHelicobacter abundance
Study
mousen: not reported in source
pre-aging male C57BL/6 mice
Outcome group
Gut microbiota · Gastrointestinal
Studied dose
Dose not stated · oralAs given in this study (mouse).
Source sentences
Summary
Nicotinamide mononucleotide significantly reduced the fecal bacterial diversity (p Helicobacter, Mucispirillum, and Faecalibacterium, and lowered Akkermansia abundance associated with nicotinamide metabolism.
1 context sentence(design, population, supporting numbers)
Summary · context
We probed the changes in the fecal microbiota and metabolomes of pre-aging male mice (C57BL/6, age: 16 months) following the oral short-term administration of nicotinamide mononucleotide (NMN).
Show in the study text Report a problemFND-3491283806
08AnimalAnimal study (in vivo)Efficacy outcome
In pre-aging mice, NMN increased fecal Mucispirillum abundance.
In plain wordsIn pre-aging mice, NMN increased Mucispirillum abundance in feces.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
IncreaseMucispirillum abundance
Study
mousen: not reported in source
pre-aging male C57BL/6 mice
Outcome group
Gut microbiota · Gastrointestinal
Studied dose
Dose not stated · oralAs given in this study (mouse).
Source sentences
Summary
Nicotinamide mononucleotide significantly reduced the fecal bacterial diversity (p Helicobacter, Mucispirillum, and Faecalibacterium, and lowered Akkermansia abundance associated with nicotinamide metabolism.
1 context sentence(design, population, supporting numbers)
Summary · context
We probed the changes in the fecal microbiota and metabolomes of pre-aging male mice (C57BL/6, age: 16 months) following the oral short-term administration of nicotinamide mononucleotide (NMN).
Show in the study text Report a problemFND-3491283807
09AnimalAnimal study (in vivo)Efficacy outcome
In pre-aging mice, NMN increased fecal Faecalibacterium abundance.
In plain wordsIn pre-aging mice, NMN increased Faecalibacterium abundance in feces.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
IncreaseFaecalibacterium abundance
Study
mousen: not reported in source
pre-aging male C57BL/6 mice
Outcome group
Gut microbiota · Gastrointestinal
Studied dose
Dose not stated · oralAs given in this study (mouse).
Source sentences
Summary
Nicotinamide mononucleotide significantly reduced the fecal bacterial diversity (p Helicobacter, Mucispirillum, and Faecalibacterium, and lowered Akkermansia abundance associated with nicotinamide metabolism.
1 context sentence(design, population, supporting numbers)
Summary · context
We probed the changes in the fecal microbiota and metabolomes of pre-aging male mice (C57BL/6, age: 16 months) following the oral short-term administration of nicotinamide mononucleotide (NMN).
Show in the study text Report a problemFND-3491283808
10AnimalAnimal study (in vivo)Efficacy outcome
In pre-aging mice, NMN lowered fecal Akkermansia abundance associated with nicotinamide metabolism.
In plain wordsIn pre-aging mice, NMN lowered Akkermansia abundance in feces.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
DecreaseAkkermansia abundance
Study
mousen: not reported in source
pre-aging male C57BL/6 mice
Outcome group
Gut microbiota · Gastrointestinal
Studied dose
Dose not stated · oralAs given in this study (mouse).
Source sentences
Summary
Nicotinamide mononucleotide significantly reduced the fecal bacterial diversity (p Helicobacter, Mucispirillum, and Faecalibacterium, and lowered Akkermansia abundance associated with nicotinamide metabolism.
1 context sentence(design, population, supporting numbers)
Summary · context
We probed the changes in the fecal microbiota and metabolomes of pre-aging male mice (C57BL/6, age: 16 months) following the oral short-term administration of nicotinamide mononucleotide (NMN).
Show in the study text Report a problemFND-3491283809
11AnimalAnimal study (in vivo)Efficacy outcome
In pre-aging mice, NMN significantly elongated PBMC telomeres.
In plain wordsIn pre-aging mice, NMN increased telomere length in peripheral blood mononuclear cells.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
IncreasePBMC telomere length
Study
mousen: not reported in source
pre-aging male C57BL/6 mice
Outcome group
Aging markers · Aging and longevity
Studied dose
Dose not stated · oralAs given in this study (mouse).
Source sentences
Summary
Most notably, the telomere length of PBMC was significantly elongated in the NMN-administered mice and humans.
1 context sentence(design, population, supporting numbers)
Summary · context
We probed the changes in the fecal microbiota and metabolomes of pre-aging male mice (C57BL/6, age: 16 months) following the oral short-term administration of nicotinamide mononucleotide (NMN).
Show in the study text Report a problemFND-3491283810

Studies that did not test the peptide alone1

In this study, NMN (nicotinamide mononucleotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking NMN (nicotinamide mononucleotide).

12Computer modelNot a test of NMN (nicotinamide mononucleotide) aloneIn silicoMechanism
In microbiota analysis after NMN treatment in mice, the authors proposed reduced predicted aging functions and improved immune and cofactor/vitamin metabolism.
In plain wordsIn computer analysis of mouse microbiota after NMN, the authors proposed reduced predicted aging functions and improved immune and cofactor/vitamin metabolism.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
MixedPredicted microbiota functions
Study
n: not reported in source
predicted functions of reshaped fecal microbiota
Outcome group
Gut microbiota · Gastrointestinal
Source sentences
Summary
We propose that this reshaped microbiota considerably lowered the predicated functions of aging with improved immune and cofactors/vitamin metabolism.
1 context sentence(design, population, supporting numbers)
Summary · context
We probed the changes in the fecal microbiota and metabolomes of pre-aging male mice (C57BL/6, age: 16 months) following the oral short-term administration of nicotinamide mononucleotide (NMN).
In this study, NMN (nicotinamide mononucleotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking NMN (nicotinamide mononucleotide).
Show in the study text Report a problemFND-3491283812

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
21 Oct 2026, 15:58 UTC
Study results updated
Version 1
21 Oct 2026, 12:50 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.